Steinhart Richard I
SEC Form 4 insider trading activity
Steinhart Richard I has filed 8 SEC Form 4 filings (12 transaction rows) across 3 companies, including ATNM, BTAI, ATOS, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Sep 4, 2026.
On the most recent filing, Steinhart Richard I is listed as Chief Financial Officer at BioXcel Therapeutics, Inc. Inside the rolling window, Steinhart Richard I reported no open-market purchases and 1 open-market sale totaling $7K in BTAI.
Companies traded
Other insiders at ATNM
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7K
reported sales (SEC code S)
Companies
3
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Steinhart Richard I made?
Steinhart Richard I has filed 8 SEC Form 4 filings (12 transaction rows) across 3 companies, including ATNM, BTAI, ATOS since 2025.
Which companies does Steinhart Richard I trade?
Steinhart Richard I has filed SEC Form 4 disclosures for 3 companies, including ATNM, BTAI, ATOS.
When was Steinhart Richard I's most recent SEC Form 4 filing?
Steinhart Richard I's most recent SEC Form 4 filing on Tracefour is dated Sep 4, 2026.
What is Steinhart Richard I's total buy and sell value in the current window?
Inside the rolling retention window, Steinhart Richard I bought $0 and sold $7K based on SEC Form 4 filings.
What was Steinhart Richard I's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,845 BTAI shares on 2026-05-20, worth $7K, per SEC Form 4 filings.